Thousands of statin users worldwide are suffering preventable heart attacks, simply because they are not complying with their treatment or are taking too low a dose, according to new research published on-line today (Thursday 7 December) in European Heart Journal.
These life-saving drugs, used to lower cholesterol levels in people at risk of coronary heart disease (CHD), can only be optimally effective if patients use them properly – and many are not.
That is the conclusion by the research team, who followed the prescription records of nearly 60,000 patients in the Netherlands for up to 14 years.
Dr Fernie Penning-van Beest and colleagues from the PHARMO Institute, the Utrecht Institute of Pharmaceutical Sciences and the Academic Hospital in Amsterdam, analysed 548,084 prescriptions of statin treatment issued over the first two years of treatment in 59,094 new users in the period January 1991-December 2004, and followed the patients until their first hospital admission for heart attack, death, or the end of the study in December 2004.
The aim was to see how effective robust statin treatment was for primary and secondary CHD in the ‘real world’ – as opposed to in clinical trials. Their results enabled them to calculate the absolute number of avoidable heart attacks that occurred because patients had stopped taking their drugs or were not taking them consistently. They were also able to compare the preventive effects of different doses and types of statins.
Patients were divided into two groups – those at high risk of heart attack and those at intermediate or low risk, with over a fifth of patients (12,762) considered high risk.
They found more than half of all patients (31,557) stopped taking statins within two years and only just over a third (20,883) were persistent users on a high or intermediate dose.
Among persistent users, hospital admission for heart attacks fell by nearly a third (30%) compared to non-persistent users, in both primary and secondary prevention groups. In the primary prevention group, admission was down from 0.52 per 100 patient years among non-persistent users to 0.42 per 100 patient years in persistent users. In the secondary prevention group it was down from 0.86 to 0.62.
Among patients using the high or intermediate doses the risk reduction was as high as 40%, while a low dose reduced the risk by only 20%.
The researchers calculated that, every year, around 300 to 400 statin users in the Netherlands have an avoidable heart attack because of sub-optimal doses or discontinuing treatment. They believe the results are likely to be typical of Europe as a whole and of the USA, which means 7,000 to 9,000 Europeans and 5,000 to 7,000 Americans a year are suffering unnecessary heart attacks.
“What this clearly tells us,” said lead researcher Dr Penning-van Beest, a research associate at the PHARMO Institute, “is that our observational study supports robust cholesterol lowering, as recommended on the basis of clinical trials. But, drugs are only really effective if they are used properly and persistently. Unfortunately, statins are not being used optimally, so thousands of people are having unnecessary heart attacks. Getting users to stay on statins and to use them persistently saves lives, and doctors must get over to patients the message that complying with treatment is essential.”
Different types of statins are used in different doses, so the researchers dealt with these differences by grading the five statins they assessed for equipotency (the dose of one type of statin needed to achieve the same effect as another type).
They found that as well as the largest reduction in heart attacks needing hospital admission being among patients consistently taking the drugs over the whole two-year period at persistently high or intermediate equipotent doses, these patients were also relatively more likely to be using second generation statins i.e. atorvastatin or rosuvastatin, rather than the first generation types, pravastatin, fulvastatin or simvastatin. Higher doses of first generation statins were being prescribed, but increasing the dose of these older statins is limited by the maximum safe dose.
Co-author Dr Ron Herings, scientific director of the PHARMO Institute and associate professor of pharmacoepidemiology at Utrecht University, said: “It is preferable to achieve a high equipotent dose by using the new, highly potent statins. But, the new statins have considerable economic impact on pharmaceutical budgets and the opposite trend is being encouraged in the Netherlands and Germany, where reimbursement measures promote the use of relatively inexpensive generic older types.”
He said: “This is fine, as long as guidelines for higher doses of these older statins are implemented, and bearing in mind that there may be limitations to giving the highest doses. But, restricting the use of older generic statins to standard low doses will make the problems worse.
“Ideally, to improve the population effectiveness of statin treatment, persistent drug use and the use of new, potent statins, should be encouraged.” he concluded.The research was funded by an unrestricted grant from Nefarma – the Dutch association of pharmaceutical industries. But, the study was designed, conducted and analysed entirely independently of the funders.
Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. European Heart Journal. doi:10.1093/eurheartj/ehl391.
PHARMO Institute: an independent scientific research organisation dedicated to studying drug use and outcomes in daily practice.
The reduction of serum cholesterol levels is associated with a considerably lower risk of coronary heart disease (CHD) among high-risk patients and individuals without cardiovascular risk factors. The benefits of reducing cholesterol levels are obtained early, the major part after two years of treatment and the full benefit only after five years.
Margaret Willson | alfa
Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University
The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.
Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
02.12.2016 | Medical Engineering
02.12.2016 | Agricultural and Forestry Science
02.12.2016 | Physics and Astronomy